ZBH

Business Context and Reporting Period

Company: Zimmer Holdings, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: Zimmer is a global leader in the design, development, manufacture, and marketing of reconstructive orthopaedic implants (joint, dental, spinal, trauma) and related surgical products. Operations are managed through three geographic segments: Americas, Europe, and Asia Pacific.

Key Financial Metrics

Material Changes vs. Prior Period

• Settlement Expense: The most significant material change was a $169.5 million settlement expense recorded in the third quarter of 2007. This relates to a settlement with the U.S. government regarding financial relationships between orthopaedic manufacturers and consulting surgeons. No tax benefit was recorded for this expense.
• Profitability Impact: Due to the settlement, Operating Profit for the three months ended September 30, 2007, decreased 50% to $126.0 million from $254.5 million in the prior year. Net Earnings decreased 76% to $44.5 million from $183.3 million.
• Revenue Growth: Net Sales increased 10% year-over-year for the quarter ($903.2M vs $819.8M) and 10% for the nine-month period ($2,824.0M vs $2,561.8M). Growth was driven by volume/mix increases (8%) and foreign exchange rates (2%), while pricing remained flat.
• Acquisitions: The company acquired Endius Incorporated (spinal products) for approximately $80 million and Diadent Srl. (dental distributor in Italy) during the period. Cash used for acquisitions totaled $108.1 million for the nine months.
• Stock Repurchases: The company repurchased 5.6 million shares for $460.6 million during the nine-month period, a decrease from $630.9 million in the prior year period.

Guidance, Outlook, Risks, and Unusual Items

• Deferred Prosecution Agreement (DPA): As part of the settlement, Zimmer entered into an 18-month DPA with the U.S. Attorney's Office. The company expects to incur compliance costs of approximately $6–9 million per quarter starting in Q4 2007.
• Corporate Integrity Agreement (CIA): A five-year agreement with the Office of Inspector General (OIG-HHS) requires enhanced compliance programs and independent reviews.
• Antitrust Investigation: The company is cooperating with a U.S. Department of Justice Antitrust Division investigation regarding potential price-fixing. Related class-action lawsuits were dismissed without prejudice pending the outcome of the government investigation.
• Foreign Corrupt Practices Act (FCPA): The SEC initiated an informal investigation in September 2007 regarding potential FCPA violations in foreign markets.
• Product Outlook: Management expects continued growth driven by new products (e.g., Gender Solutions Knee, Trabecular Metal Technology) and an aging global population. However, pricing pressure from government reimbursement cuts in Europe and Japan is expected to persist.
• Liquidity: The company maintains a $1.35 billion revolving credit facility with $1.25 billion available. Management believes cash flows and available borrowings are sufficient to meet needs.

Investor Verification Checklist

• Settlement Tax Treatment: Verify the final tax treatment of the $169.5 million settlement expense, as no benefit was initially recorded.
• Compliance Costs: Monitor actual quarterly costs associated with the DPA and CIA against the estimated $6–9 million range.
• Antitrust Resolution: Track the status of the DOJ Antitrust Division investigation and the potential for future litigation or penalties.
• FCPA Investigation: Follow developments in the SEC's informal investigation regarding foreign sales practices.
• Inventory Levels: Review inventory days (330 days as of Sep 30, 2007), which increased significantly due to new product launches, to ensure no obsolescence risks.
• Reimbursement Pressures: Assess the impact of government price cuts in key markets (Germany, France, Italy, Japan) on future gross margins.